NCT04602650

Brief Summary

Type 2 diabetes (T2D) predisposes individuals to neurodegeneration and dementia, including Alzheimer's Disease (AD); yet the link between metabolic and neurodegenerative disorders remains unknown. Here, the investigators will study a well-defined human population with increased prevalence and early onset of both T2D and AD, individuals of Mexican descent living in South Texas. The study will begin to explore the possibility that disruption of the structure of the bacterial community residing in the gut in type 2 diabetic individuals of Mexican descent living in South Texas is directly related to the increased prevalence of early onset AD in this population. In this study, the investigators will perform gene sequencing on DNA isolated from fecal samples to identify and compare the populations of bacteria living in individuals with T2D versus non-diabetic controls. The investigators will analyze the findings to determine if the community structure of the gut microbiome of individuals of Mexican descent with T2D is significantly altered compared to that of non-diabetics within the same population. The investigators' findings could lead to the identification of early indicators of dementia onset as well as novel therapies for treating metabolic and neurodegenerative diseases.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jan 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 20, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

October 26, 2020

Completed
3 months until next milestone

Study Start

First participant enrolled

January 14, 2021

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2022

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2022

Completed
Last Updated

February 15, 2023

Status Verified

February 1, 2023

Enrollment Period

1.4 years

First QC Date

October 20, 2020

Last Update Submit

February 14, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Fecal Microbial Gene Sequencing

    Metagenomic 16S ribosomal RNA (rRNA) gene sequencing will be performed on subject samples to determine the presence and measure the relative abundance of operational taxonomic units representative of bacterial genera, species, and strains present in the fecal sample.

    Baseline

Secondary Outcomes (3)

  • Gastrointestinal health as measured by gastrointestinal symptom rating scale

    Baseline

  • Food Preference Questionnaire

    Baseline

  • Neurological History Questionnaire

    Baseline

Study Arms (2)

Type 2 Diabetic

Type 2 diabetic individuals of Mexican descent.

Non-diabetic Controls

Non-diabetic individuals of Mexican descent.

Eligibility Criteria

Age50 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

We will study subjects of Mexican descent living in Texas (aged 50-70 years) with a history of type 2 diabetes (T2D) (n=50, anticipated) and non-diabetic controls (aged 50 - 70 years) (n=50, anticipated).

You may qualify if:

  • Male or female with a diagnosis of type 2 diabetes.
  • Ages 50 to 70 years.
  • Mexican descent living in Texas.
  • Participant is willing and able to give informed consent for participation in the study.
  • Male or female without history of type 2 diabetes.
  • Ages 50 to 70 years.
  • Mexican descent living in Texas.
  • Participant is willing and able to give informed consent for participation in the study.

You may not qualify if:

  • Hypertension that is not controlled by greater than 2 medications.
  • Chronic kidney disease, CKD greater than 3.
  • History of coronary bypass or stint placement.
  • Current pregnancy.
  • Subjects with a history of inflammatory bowel disease, Celiac disease or active diverticular disease.
  • Hypertension that is not controlled by greater than 2 medications.
  • Chronic kidney disease, CKD greater than 3.
  • History of coronary bypass or stint placement.
  • Current pregnancy.
  • Subjects with a history of inflammatory bowel disease, Celiac disease or active diverticular disease.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Texas Medical Branch

Galveston, Texas, 77555, United States

Location

Related Publications (1)

  • Matz LM, Shah NS, Porterfield L, Stuyck OM, Jochum MD, Kayed R, Taglialatela G, Urban RJ, Buffington SA. Gut pathobiont enrichment observed in a population predisposed to dementia, type 2 diabetics of Mexican descent living in South Texas. Front Microbiomes. 2024;3:10.3389/frmbi.2024.1456642. doi: 10.3389/frmbi.2024.1456642. Epub 2024 Dec 3.

Biospecimen

Retention: SAMPLES WITH DNA

Fecal bacterial DNA specimens will be retained.

MeSH Terms

Conditions

Diabetes Mellitus

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Officials

  • Shelly Buffington, PhD

    University of Texas Medical Branch Galveston

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 20, 2020

First Posted

October 26, 2020

Study Start

January 14, 2021

Primary Completion

May 31, 2022

Study Completion

December 31, 2022

Last Updated

February 15, 2023

Record last verified: 2023-02

Data Sharing

IPD Sharing
Will not share

We do not plan to make individual participant data (IPD) available to other researchers.

Locations